Entrada Therapeutics (Entrada Therapeutics) EV-to-EBIT : -41.61 (As of Apr. 26, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Entrada Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Entrada Therapeutics's Enterprise Value is $131.6 Mil. Entrada Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.2 Mil. Therefore, Entrada Therapeutics's EV-to-EBIT for today is -41.61.

The historical rank and industry rank for Entrada Therapeutics's EV-to-EBIT or its related term are showing as below:

TRDA' s EV-to-EBIT Range Over the Past 10 Years
Min: -83.04 Med: -5.24 Max: 0.2
Current: -41.61

During the past 5 years, the highest EV-to-EBIT of Entrada Therapeutics was 0.20. The lowest was -83.04. And the median was -5.24.

TRDA's EV-to-EBIT is ranked worse than
100% of 442 companies
in the Biotechnology industry
Industry Median: 8.41 vs TRDA: -41.61

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Entrada Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $220.8 Mil. Entrada Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.2 Mil. Entrada Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1.43%.

Entrada Therapeutics EV-to-EBIT Historical Data

The historical data trend for Entrada Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entrada Therapeutics EV-to-EBIT Chart

Entrada Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-4.76

-2.69

-69.84

Entrada Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial											-2.69	-1.06	-2.70	-7.20	-69.84

Competitive Comparison of Entrada Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Entrada Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entrada Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's EV-to-EBIT falls into.

Entrada Therapeutics EV-to-EBIT Calculation

Entrada Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	131.571	/	-3.162
	=	-41.61

Entrada Therapeutics's current Enterprise Value is $131.6 Mil.
Entrada Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.2 Mil.

Entrada Therapeutics (NAS:TRDA) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Entrada Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-3.162	/	220.829857
	=	-1.43 %

Entrada Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $220.8 Mil.
Entrada Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.2 Mil.

Entrada Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Entrada Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Entrada Therapeutics (Entrada Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entrada Therapeutics Inc (NAS:TRDA) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Tide Street, Boston, MA, USA, 02210

Website

https://www.entradatx.com

Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.

Executives

Dipal Doshi	director, officer: President and CEO	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Kory James Wentworth	officer: Chief Financial Officer	6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210
Nathan J Dowden	officer: Chief Operating Officer	6 TIDE STREET, BOSTON MA 02210
Nerissa Kreher	officer: Chief Medical Officer	C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Gina Chapman	director	C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403
Natarajan Sethuraman	officer: Chief Scientific Officer	6 TIDE STREET, BOSTON MA 02210
Bernhardt G Zeiher	director	ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210
Baker Bros. Advisors Lp	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Todd Foley	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116
Felix Baker	10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
John F Crowley	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Redmile Group, Llc	10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Mpm Bioventures 2018, L.p.	10 percent owner	450 KENDALL STREET, CAMBRIDGE MA 02142